References
- Dougherty SH, Simmons RL. Infections in bionic man: the pathobiology of infections in prosthetic devices (parts I and II). Curr Probl Surg 1982; 19: 219-264, 268–319.
- Vaudax PE, Zulian G, Huggler E, Waldvogel FA. Attachment of Staphylococcus aureus to polymethyl-methacrylate increases its resistance to phagocytosis in foreign body infections. Infect Immunol 1985; 50: 472–477.
- Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue infiltration. Science 1987; 237: 1588–1595.
- Zimmerly W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest 1984; 73: 1191–1200.
- Venditti M, Baiocchi P, Brandimarte C, Capone A, Tarasi A. High rate of oxacillin-resistant Staphylococcus aureus isolates in an Italian university hospital. J Chemother 1994; 6: 25–28.
- Baiocchi P, Capone A, Carfagna P, Santini C, Venditti M. Changes in susceptibilities to teicoplanin, vancomycin and other antibiotics among Staphylococcus aureus isolates in a tertiary-care university hospital. Int J Antimicrob Agents 1996; 7: 93–96.
- Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clini-cal strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135–136.
- Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampicin therapy among patients with methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674–680.
- Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methi-cillin-resistance Staphylococcus aureus infection. N Engl J Med 1999; 340: 517–523.
- Barman Balfour JA, Lamb HM. Moxifloxacin. A review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59: 115–139.
- Tarasi A, Capone A, Tarasi D, Cassone M, Bianco G, Venditti M. Comparative in vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis. J Antimicrob Chemother 1999; 43: 833-835.
- Woods GL, Washington JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In P. R. Murray (ed), Manual of Clinical Microbiology, 6h ed. ASM press Washington, 1995: 1327-41.
- Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of Moxifloxacin, a new fluoro-quinolone. Antimicrob Agents Chemother 1997; 41: 101–106.
- Eliopoulos GM, Moellering, Jr RC. Antimicrobial combi-nation, p. 432-492. In V. Lorian (ed.), Antibiotics in laboratory medicine, 3rd ed. The Williams & Wilkins Co., Baltimore, 1991.
- Mato R, Santos Sanchez I, Venditti M, et al. Spread of the multidrug resistant Iberian clone of methicillin-resistant Staphylococcus aureus (MRSA) to Italy and Scotland. Microb. Drug Resist. 1998; 4: 107–112.
- Hoogkamp-Korstanje JAA. Activity of moxifloxacin against Gram-positive cocci. 8th European Congress of Clinical Microbiology and Infectious Diseases. Lausanne, Switzerland 25-28 May 1997.
- Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227–1231.
- Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 813-815.
- Burnie J, Matthew R, Jiman-Fatami A, Gottardello P, Hodgetts S, D'arcy S. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to van-comycin. Clin Infect Dis 2000; 31: 684–90.